TransBioNet is a Horizon Europe Coordination and Support Action building the first European network of organisations that help turn biomedical discoveries into medicines and market-ready solutions.
Project goal – to help promising early-stage drug discovery projects across Europe become investment-ready and to narrow the gap between laboratory discoveries and therapies that reach patients.
Project activities – a shared digital platform for learning, matchmaking and project assessment; a Valorisation Assessment Toolkit; a European Infrastructure Atlas; a Digital Training Academy and cross-border secondments; two Open Calls selecting 12 early-stage drug discovery projects for a 12-month acceleration programme; and the TransBioNet Charter with policy recommendations at EU and national level.
LithuaniaBIO’s role – represents the Lithuanian ecosystem, coordinates cross-border secondments between European ecosystems, contributes to the analysis of national policies and disseminates project results and opportunities in Lithuania.
Project partners:
Associação Accelbio (coordinator, Portugal)
Biocant Park (Portugal)
EATRIS ERIC (the Netherlands)
EIT Health InnoStars e.V. (Germany)
Danish Life Science Cluster (Denmark)
Health & Life Sciences Cluster Bulgaria (Bulgaria)
LithuaniaBIO (Lithuania)
Project start: 2026-09-01 | Project end: 2029-08-31
Project budget: €1,964,375 | Grant Agreement No. 101291691
Follow TransBioNet on LinkedIn: https://www.linkedin.com/company/transbionet/
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101291691.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.